You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Addressing Persistent Myths and Misconceptions in Tardive Dyskinesia

  • Authors: Rakesh Jain, MD, MPH (Chair); Craig Chepke, MD, FAPA; Kevin Williams, MS, MPAS, PA-C; Bethany Yeiser, BS; David Yeiser
  • CME / CE Released: 12/23/2022
  • Valid for credit through: 12/23/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    Nurses - 1.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Psychologists - 1.25 APAPO Continuing Education Credit(s)

    Nurse Practitioners - 1.25 AANP Contact Hours (0 contact hours are in the area of pharmacology)

    Physician Assistant - 1.00 AAPA hour(s) of Category I credit

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is designed for psychiatrists, psychiatric nurse practitioners (NPs), advanced practice nurses (APRNs), physician assistants (PAs), primary care practitioners, nurses, and the full multidisciplinary team of behavioral health professionals, such as psychologists, social workers, counselors, Veterans Affairs-affiliated practitioners, criminal justice professionals, community advocates, and others who seek to improve the care of patients with mental health disorders.

The goal of this session is to address the myths and misconceptions among clinicians and stakeholders from a variety of disciplines about TD to improve TD management and positively impact patient outcomes and quality of life.

Upon completion of this activity, participants will:

  1. Discuss with patients the quality of life impact that even low Abnormal Involuntary Movement Scale (AIMS) scores may have in addition to stigma associated with TD.
  2. Describe the clinical risk factors for the development of TD, the prevalence of TD in patients currently taking antipsychotic medication, and the impact on patient quality of life.
  3. Utilize mechanism of action (MOA), key clinical trial data, and current guideline recommendations to appropriately implement and/or adjust therapy for TD symptom management without specialist referral.
  4. Describe why anticholinergics are not recommended for TD treatment.
  5. Implement strategies to ensure appropriate novel vesicular monoamine transporter 2 (VMAT2) dosage for each individual patient.


Disclosures

Disclosure of Relevant Financial Relationships

HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real relevant financial relationship (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME and CPME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

  1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
  2. Any investigational, off-label, or non-FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified financial relationships (conflicts of interest), and ensure:

  1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis. 
  3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

All relevant financial relationships have been mitigated.


Faculty

  • Rakesh Jain, MD, MPH

    Clinical Professor
    Department of Psychiatry
    Texas Tech Health Sciences Center
    School of Medicine
    Midland, Texas

    Disclosures

    Disclosure: Rakesh Jain, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie (Allergan); Acadia; Adamas; Alfasigma USA, Inc.; Alkermes; Axsome; Cingulate Therapeutics; Corium; Eisai; Evidera; Impel NeuroPharma; Indivior; Intra-Cellular Therapies; Ironshore Pharmaceuticals; Janssen; Lilly; Lundbeck; Merck; Neos Therapeutics; Neurocrine Biosciences, Inc.; Osmotica; Otsuka; Pamlab; Pfizer, Inc.; Sage Therapeutics; Shire; Sunovion; Supernus; Takeda; Teva Pharmaceuticals; Tris Pharmaceuticals
    Speaker or member of speakers bureau for: AbbVie (Allergan); Alkermes; Axsome; Corium; Eisai; Indivior; IntracellularTherapies; Ironshore Pharmaceuticals; Janssen; Lilly; Lundbeck; Merck; Neos Therapeutics; Neurocrine Biosciences, Inc.; Otsuka; Pamlab; Pfizer, Inc.; Shire; Sunovion; Takeda; Teva Pharmaceuticals; Tris Pharmaceuticals
    Research funding from: AbbVie (Allergan); Lilly; Lundbeck; Otsuka; Pfizer, Inc.; Shire; Takeda
    Other; Advisory board (spouse): Otsuka
    Other; Consultant (spouse): Lilly; Otsuka; Pamlab; Sunovion
    Other' Speakers bureau (spouse): Lilly

  • Craig Chepke, MD, FAPA

    Medical Director
    Excel Psychiatric Associates
    Clinical Assistant Professor of Psychiatry
    SUNY Upstate Medical University
    Syracuse, New York
    Adjunct Associate Professor of Psychiatry
    Atrium Health
    Huntersville, North Carolina

    Disclosures

    Disclosure: Craig Chepke, MD, FAPA, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Acadia; Alkermes; Corium; Eisai; Idorsia; Intracellular; Ironshore; Janssen; Jazz; Karuna; Lundbeck; Neurocrine Biosciences, Inc.; Noven; Otsuka; Takeda; Teva Pharmaceuticals
    Speaker or member of speakers bureau for: AbbVie; Acadia; Alkermes; Eisai; Intracellular; Ironshore; Janssen; Jazz; Lundbeck; Merck; Neurocrine Biosciences, Inc.; Noven; Otsuka; Sunovion; Takeda; Teva Pharmaceuticals
    Research funding from: Acadia; Axsome; Biohaven; Harmony; Neurocrine Biosciences, Inc.; Teva Pharmaceuticals
    Other; Advisory Board (Spouse): Otsuka

  • Kevin Williams, MS, MPAS, PA-C

    CEO and Lead Clinician
    OnPoint Behavioral Health
    Tampa, Florida

    Disclosures

    Disclosure: Kevin Williams, MS, MPAS, has the following relevant financial relationships:
    Speaker or member of speakers bureau for: Myriad; Neurocrine Biosciences, Inc.; Teva Pharmaceuticals

  • Bethany Yeiser, BS

    Patient Advocate
    President
    CureSZ Foundation
    Fairfield, Ohio

    Disclosures

    Disclosure: Bethany Yeiser, BS, has the following relevant financial relationships:
    Consultant or advisor for: Alkermes
    Speaker or member of speakers bureau for: Alkermes; Neurocrine Biosciences, Inc.
    Research funding from: Cadent Therapeutics; Janssen; Karuna Therapeutics; Neurocrine Biosciences, Inc.

  • David Yeiser

    Father of Patient Advocate
    Fairfield, Ohio

     

    Disclosures

    Disclosure: David Yeiser has no relevant financial relationships.

Additional Planners and Reviewers

  • Clinical Reviewer

    William C. Torrey, MD

    Professor and Vice Chair for Clinical Services
    Dartmouth’s Geisel School of Medicine
    Dartmouth-Hitchcock
    Lebanon, New Hampshire

    Disclosures

    William C. Torrey, MD, has no relevant financial relationships.

HMP Education planners and staff include Meaghan Benci, Robert Carroll, Samantha Joy, Kathleen Hines, Mary Johnson, Randy Robbin, Michelle Stewart, Gina Rescinito, and Andrea Zimmerman.   

The HMP Education planners or staff listed above have no relevant financial relationships. 

The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational use(s) of drugs, products, and/or devices (any use not approved by the US Food and Drug Administration). 

The off-label use of amantadine, clonazepam, botulinum toxin, deep brain stimulation, Ginkgo biloba, and tetrabenazine for the treatment of tardive dyskinesia will be discussed. 

Applicable CME staff have no relationships relating to the subject matter of this activity. 

This activity has been independently reviewed for balance. 


Accreditation Statements



In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • HMP Education designates this live activity for a maximum of X.X AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    HMP Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Contact This Provider

    For Nurses

  • Awarded ​X.XX​ contact hour(s) of nursing continuing professional development for RNs and APNs; ​X.XX​ contact hours are in the area of pharmacology.

    This continuing nursing education internet enduring activity awards 1.25 contact hours. 

    Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.25 contact hours. 

    For Nurse Practitioners

    American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

    Contact This Provider

    For Psychologists

  • APA Logo Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. 

    APA Logo Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. 

    Contact This Provider

  • For Physician Assistants

    HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.25 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

    Contact This Provider

    For Social Workers

    As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.25 general continuing education credits.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Addressing Persistent Myths and Misconceptions in Tardive Dyskinesia

Authors: Rakesh Jain, MD, MPH (Chair); Craig Chepke, MD, FAPA; Kevin Williams, MS, MPAS, PA-C; Bethany Yeiser, BS; David YeiserFaculty and Disclosures

CME / CE Released: 12/23/2022

Valid for credit through: 12/23/2023

processing....

Pre-Assessment Questions

  • Print